Adding Citius (CTXR) $0.55 to Watch List.
Disclaimer. Citius Pharma is a client, please see reports for disclosure and disclaimer details.
- Biotech News
- 2020 Watch List
- 2021 Watch List
- All News
- Client
- CoronaVirus
- Incubator
- Infections
- Institutional Analyst Newsletter
- Interview
- Stem Cells
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
Latest article
Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...
Major Mpox Outbreak in the Democratic Republic of Congo.
As Reported in NPR's Gates and Soda
Major Mpox Outbreak in the Democratic Republic of Congo is a...
Mpox Infections Rise to Almost Double Last Year’s Numbers.
The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of...
